Heska Corporation (NASDAQ: HSKA) and IDEXX Laboratories (NASDAQ:IDXX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitabiliy and valuation.

Volatility & Risk

Heska Corporation has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500.

Institutional and Insider Ownership

81.8% of Heska Corporation shares are held by institutional investors. Comparatively, 89.1% of IDEXX Laboratories shares are held by institutional investors. 14.7% of Heska Corporation shares are held by insiders. Comparatively, 2.8% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Heska Corporation and IDEXX Laboratories’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Heska Corporation $133.32 million 5.38 $21.99 million $1.87 53.89
IDEXX Laboratories $1.82 billion 8.06 $449.79 million $2.71 61.44

IDEXX Laboratories has higher revenue and earnings than Heska Corporation. Heska Corporation is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Heska Corporation and IDEXX Laboratories’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Heska Corporation 10.45% 15.20% 10.96%
IDEXX Laboratories 13.47% -706.91% 15.74%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Heska Corporation and IDEXX Laboratories, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heska Corporation 0 4 2 0 2.33
IDEXX Laboratories 2 2 2 0 2.00

Heska Corporation presently has a consensus target price of $94.13, suggesting a potential downside of 6.60%. IDEXX Laboratories has a consensus target price of $161.00, suggesting a potential downside of 3.30%. Given IDEXX Laboratories’ higher probable upside, analysts clearly believe IDEXX Laboratories is more favorable than Heska Corporation.

Summary

IDEXX Laboratories beats Heska Corporation on 9 of the 13 factors compared between the two stocks.

Heska Corporation Company Profile

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products. Its OVP segment includes private label vaccine and pharmaceutical production for cattle but also for other species, including equine, porcine, avian, feline and canine. All OVP products are sold by third parties under third-party labels. It focuses on supporting veterinarians in canine and feline healthcare space. It offers a line of veterinary blood testing and other instruments. It manufactures biological and pharmaceutical products for other animal health companies.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.

Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.